Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
ACS Infect Dis ; 7(8): 2455-2471, 2021 08 13.
Artigo em Inglês | MEDLINE | ID: mdl-34279922

RESUMO

Chagas disease, an infectious condition caused by Trypanosoma cruzi, lacks treatment with drugs with desired efficacy and safety profiles. To address this unmet medical need, a set of trypanocidal compounds were identified through a large multicenter phenotypic-screening initiative and assembled in the GSK Chagas Box. In the present work, we report the screening of the Chagas Box against T. cruzi malic enzymes (MEs) and the identification of three potent inhibitors of its cytosolic isoform (TcMEc). One of these compounds, TCMDC-143108 (1), came out as a nanomolar inhibitor of TcMEc, and 14 new derivatives were synthesized and tested for target inhibition and efficacy against the parasite. Moreover, we determined the crystallographic structures of TcMEc in complex with TCMDC-143108 (1) and six derivatives, revealing the allosteric inhibition site and the determinants of specificity. Our findings connect phenotypic hits from the Chagas Box to a relevant metabolic target in the parasite, providing data to foster new structure-activity guided hit optimization initiatives.


Assuntos
Doença de Chagas , Tripanossomicidas , Trypanosoma cruzi , Doença de Chagas/tratamento farmacológico , Humanos , Sulfonamidas , Tripanossomicidas/farmacologia
2.
Methods Mol Biol ; 2116: 773-780, 2020.
Artigo em Inglês | MEDLINE | ID: mdl-32221954

RESUMO

The advances in development and popularization of automated fluorescence microscopes and pipetting robots allowed scientists to establish high-throughput compound screening using image-based assays for Trypanosoma cruzi intracellular forms, which are associated to chronic Chagas disease. An intracellular T. cruzi image-based assay is a valuable tool to early stage drug discovery for Chagas disease, because it allows scientists to assess a compound's efficacy and safety in the same experiment. During the last 10 years, several improvements have been incorporated into intracellular T. cruzi assay protocols to make them more predictable in what happens with parasites within an infected organism. In the present chapter, a protocol will be presented for an intracellular T. cruzi assay, but at a low-throughput scale, more compatible with facilities in many academic laboratories.


Assuntos
Doença de Chagas/tratamento farmacológico , Descoberta de Drogas/métodos , Processamento de Imagem Assistida por Computador , Tripanossomicidas/farmacologia , Trypanosoma cruzi/efeitos dos fármacos , Animais , Linhagem Celular , Doença de Chagas/parasitologia , Chlorocebus aethiops , Doença Crônica , Células Epiteliais/parasitologia , Humanos , Estágios do Ciclo de Vida/efeitos dos fármacos , Microscopia de Fluorescência/instrumentação , Microscopia de Fluorescência/métodos , Miócitos Cardíacos/parasitologia , Testes de Sensibilidade Parasitária/métodos , Ratos , Tripanossomicidas/uso terapêutico , Trypanosoma cruzi/fisiologia
SELEÇÃO DE REFERÊNCIAS
Detalhe da pesquisa